Incysus Therapeutics to Present at Solebury Trout Private Company Showcase

New York, New York, UNITED STATES


NEW YORK, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, today announced that the Company will present an overview of the company and at the upcoming Summer Private Company Showcase 2020 hosted by Solebury Trout, Piper Sandler and White & Case. During the 20-minute presentation, participants will be able to submit questions electronically with answers provided at the discretion of the company on an individual basis afterwards.  Details are as follows:

WHO:William Ho, President, CEO, and co-founder, Incysus Therapeutics
WHAT:Incysus Therapeutics at the Solebury Trout Private Company Showcase
WHEN:Monday, August 10, 2020 at 3:00 p.m. Eastern Time
LINK:To access the presentation, please login HERE

Incysus is currently enrolling patients in two Phase 1 clinical trials.  In February of 2020, Incysus initiated enrollment in a Phase 1 study of gamma-delta T cell immunotherapy in leukemia patients undergoing allogeneic stem cell transplantation.  That study, the first trial of an ex-vivo expanded and activated, allogeneic gamma-delta immunotherapy, is being conducted at the University of Kansas Cancer Center.  Additionally, in February of 2020, the Company also initiated enrollment in a Phase 1 study of patients with newly diagnosed glioblastoma. That study is being conducted at the University of Alabama at Birmingham.  Incysus’ Drug Resistant Immunotherapy (DRI) is the first genetically engineered gamma-delta T cell therapy to be administered to patients.

About Incysus Therapeutics, Inc.
Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, the Company’s technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. Incysus’ immuno-oncology programs include activated and gene-modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. The Company’s first clinical program is targeted to leukemia and lymphoma and its second program is targeted for the treatment of newly diagnosed glioblastoma (GBM). Information about the Company’s clinical trial in GBM can be found here (NCT04165941) and for leukemia can be found here (NCT03533816). For more information about the Company and its programs, visit www.Incysus.com.

Forward Looking Statements
Certain statements herein concerning the Company’s future expectations, plans and prospects, including without limitation, the Company’s current expectations regarding its business strategy, product candidates, and clinical development process and timing, constitute forward-looking statements. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” the negative of these and other similar expressions are intended to identify such forward looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company’s control. Consequently, actual future results may differ materially from the anticipated results expressed in such statements. In the case of forward-looking statements regarding investigational product candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from the Company’s current expectations include: scientific, regulatory and technical developments; failure to demonstrate safety, tolerability and efficacy; final and quality controlled verification of data and the related analyses; expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration; and the Company’s reliance on third parties, including licensors and clinical research organizations. Do not place undue reliance on any forward-looking statements included herein, which speak only as of the date hereof and which the Company is under no obligation to update or revise as a result of any event, circumstances or otherwise, unless required by applicable law.

Contact:
Incysus Therapeutics, Inc.
William Ho, President & CEO
who@Incysus.com
+1 646.600.6GDT
info@Incysus.com
www.Incysus.com